Literature DB >> 8001219

Halothane and isoflurane preferentially inhibit prostanoid-induced vasoconstriction of rat aorta.

M Yamamoto1, Y Hatano, M Kakuyama, H Hirakata, H Toda, N Seo, M Nishiwada, K Nakamura, K Mori.   

Abstract

In a previous study, we demonstrated that halothane and isoflurane inhibit binding of thromboxane A2 to its receptors on human platelets and thus inhibit prostanoid-induced aggregation strongly. The aim of this study was to determine whether volatile anaesthetics inhibit prostanoid-induced vasoconstriction preferentially. Rat isolated aortic rings were mounted in organ baths and their isometric tension was measured. They were contracted with STA2 (a stable thromboxane A2 analogue), prostaglandin F2 alpha (PGF2 alpha), phenylephrine, and 20 mM KCl, and then exposed to halothane (0.5-3%), isoflurane (0.5-3%), and sodium nitroprusside (SNP, 10(-9)-3 x 10(-7) M). Halothane (2-3%) and isoflurane (2-3%) induced greater relaxation of aortic rings precontracted with STA2 and PGF2 alpha than of those precontracted with phenylephrine (P < 0.01). Halothane induced greater relaxation of rings precontracted with KCl than phenylephrine only at 3%, whereas isoflurance relaxed rings precontracted with KCl more than those with phenylephrine at 0.5, 2 and 3% (P < 0.05). In contrast, SNP relaxed rings precontracted with PGF2 alpha. KCl and phenylephrine equally, but induced smaller relaxations of those precontracted with STA2 (P < 0.05). We conclude that halothane and isoflurane inhibit prostanoid-induced vasoconstriction preferentially, possibly by interacting with prostanoid receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001219     DOI: 10.1007/BF03010943

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  14 in total

1.  Cloning and expression of cDNA for a human thromboxane A2 receptor.

Authors:  M Hirata; Y Hayashi; F Ushikubi; Y Yokota; R Kageyama; S Nakanishi; S Narumiya
Journal:  Nature       Date:  1991-02-14       Impact factor: 49.962

2.  Isoflurane-, halothane- and agonist-evoked responses in pig coronary arteries and vascular smooth muscle cells.

Authors:  J C Sill; M Ozhan; R Nelson; C Uhl
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

Review 3.  Calcium release in smooth muscle.

Authors:  H Karaki; G B Weiss
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

4.  Comparison of the direct effects of halothane and isoflurane on large and small coronary arteries isolated from dogs.

Authors:  Y Hatano; K Nakamura; T Yakushiji; M Nishiwada; K Mori; F C Anaes
Journal:  Anesthesiology       Date:  1990-09       Impact factor: 7.892

Review 5.  Cyclic guanosine monophosphate as a mediator of vasodilation.

Authors:  F Murad
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

6.  Halothane relaxes previously constricted isolated porcine coronary artery segments more than isoflurane.

Authors:  B A Bollen; J H Tinker; K Hermsmeyer
Journal:  Anesthesiology       Date:  1987-06       Impact factor: 7.892

7.  Enflurane, isoflurane, and halothane and isolated human uterine muscle.

Authors:  E S Munson; W J Embro
Journal:  Anesthesiology       Date:  1977-01       Impact factor: 7.892

8.  Halothane selectively attenuates alpha 2-adrenoceptor mediated vasoconstriction, in vivo and in vitro.

Authors:  D R Larach; H G Schuler; J A Derr; M G Larach; F A Hensley; R Zelis
Journal:  Anesthesiology       Date:  1987-06       Impact factor: 7.892

9.  Inositol trisphosphate-induced calcium release and contraction in vascular smooth muscle.

Authors:  A V Somlyo; M Bond; A P Somlyo; A Scarpa
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  Effects of prostaglandins on the cytosolic free calcium concentration in vascular smooth muscle cells.

Authors:  K Fukuo; S Morimoto; E Koh; S Yukawa; H Tsuchiya; S Imanaka; H Yamamoto; T Onishi; Y Kumahara
Journal:  Biochem Biophys Res Commun       Date:  1986-04-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.